Published in Drug Discov Today on January 04, 2010
Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol (2014) 2.23
Envisioning the future of early anticancer drug development. Nat Rev Cancer (2010) 1.67
Current status and future potential of somatic mutation testing from circulating free DNA in patients with solid tumours. Hugo J (2011) 1.13
Multiparametric analysis of cell-free DNA in melanoma patients. PLoS One (2012) 0.97
Circulating Tumor Nucleic Acids: Perspective in Breast Cancer. Breast Care (Basel) (2010) 0.85
Plasma tumor DNA: on your markers, get set, go! Ann Transl Med (2014) 0.78
Tumor-Related Methylated Cell-Free DNA and Circulating Tumor Cells in Melanoma. Front Mol Biosci (2016) 0.78
Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Cancer Res (2010) 3.54
Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol (2014) 2.23
The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. Clin Cancer Res (2010) 2.17
Remapping the insulin gene/IDDM2 locus in type 1 diabetes. Diabetes (2004) 2.02
Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer. J Thorac Oncol (2012) 1.86
EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. J Clin Pathol (2012) 1.71
The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologies. J Clin Pathol (2013) 1.30
The impact of survey nonresponse bias on conclusions drawn from a mammography intervention trial. J Clin Epidemiol (2003) 1.11
mt4216C variant in linkage with the mtDNA TJ cluster may confer a susceptibility to mitochondrial dysfunction resulting in an increased risk of Parkinson's disease in the Irish. Exp Gerontol (2003) 1.09
Targeted therapies in colorectal cancer-an integrative view by PPPM. EPMA J (2013) 0.96
Association of intercellular adhesion molecule-1 gene with type 1 diabetes. Lancet (2003) 0.95
Effect of itraconazole on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther (2003) 0.92
Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics. Clin Pharmacokinet (2006) 0.91
A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers. Clin Ther (2003) 0.89
Concordance of ATM (ataxia telangiectasia mutated) immunohistochemistry between biopsy or metastatic tumor samples and primary tumors in gastric cancer patients. Pathobiology (2013) 0.89
EGFR mutation testing practices within the Asia Pacific region: results of a multicenter diagnostic survey. J Thorac Oncol (2015) 0.88
Rapid reengineering of acute medical care for Medicare beneficiaries: the Medicare innovations collaborative. Health Aff (Millwood) (2012) 0.85
Pharmacokinetics of gefitinib in humans: the influence of gastrointestinal factors. Int J Pharm (2007) 0.82
Case studies showing clinical signs and management of cutaneous toxicity of the MEK1/2 inhibitor AZD6244 (ARRY-142886) in patients with solid tumours. Acta Oncol (2010) 0.80
Practical perspectives of personalized healthcare in oncology. N Biotechnol (2012) 0.78
(18)F-FLT-PET for Response Evaluation of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with Solid Tumors. World J Nucl Med (2012) 0.77
The unique needs of older adults readmitted to the hospital. J Am Geriatr Soc (2014) 0.75
Patients with pancreatic cancer participating in clinical trials: are targets being met, and if not, why? Pancreas (2007) 0.75